More info
Active ingredients
Methylprednisolone aceponate
Release form
Cream
Composition
100 g methylprednisolone aceponate 100 mg urea 2 g. Excipients: ethanol 96% - 100 mg, sodium chloride - 4.35 mg, disodium edetate dihydrate - 0.5 mg, 1M sodium hydroxide solution or hydrochloric acid solution - to pH 7.4-7.5, water d / and - up to 1 ml.
Pharmacological effect
Pharmacokinetics
Indications
GKS for external use. Suppresses the function of leukocytes and tissue macrophages. Limits the migration of leukocytes to the area of inflammation. Violates the ability of macrophages to phagocytosis, as well as the formation of interleukin-1. It contributes to the stabilization of lysosomal membranes, thereby reducing the concentration of proteolytic enzymes in the area of inflammation. Reduces capillary permeability due to histamine release. Suppresses the activity of fibroblasts and the formation of collagen. Inhibits the activity of phospholipase A2, which leads to the suppression of the synthesis of prostaglandins and leukotrienes. Suppresses the release of COX (mainly COX-2), which also helps to reduce the production of prostaglandins. Reduces the number of circulating lymphocytes (T-and B-cells), monocytes, eosinophils and basophils due to their movement from the vascular bed to the lymphoid tissue. inhibits the formation of antibodies. Methylprednisolone aceponon suppresses the release of ACTH and & # 946.-Lipotropin by the pituitary gland, but does not reduce the level of circulating & # 946.-Endorphin. It inhibits the secretion of TSH and FSH. When applied directly to the vessels, it causes a vasoconstrictor effect. When applied topically and locally, the therapeutic activity of methylprednisolone is due to the anti-inflammatory, antiallergic and anti-exudative (due to the vasoconstrictor effect) action.
Contraindications
Outwardly. The drug is applied 1 time / day in a thin layer on the affected skin. As a rule, the duration of continuous daily treatment with Komfoderm M2 should not exceed 12 weeks. When treating patients with lesions of the skin of the face, the course of treatment should not exceed 5 days.
Use during pregnancy and lactation
In the presence of bacterial complications and / or dermatomycosis, in addition to therapy with Komfoderm M2, specific antibacterial and / or antifungal treatment is necessary. The drug is not intended for use in ophthalmology. Avoid contact with the eyes and mucous membranes.As with the use of systemic glucocorticoids, glaucoma may develop with external use of GCS (for example, after use in high doses, due to very long use, use of occlusive dressings or applied to the skin around the eyes). On the skin of the face more often than on other surfaces of the body, after prolonged treatment of GCS for external use, atrophic changes may develop. Impact on the ability to drive vehicles and control mechanisms Not identified.
Side effects
The interaction of the drug with other drugs has not been identified, but it should be borne in mind that the simultaneous use of the drug Komfoderm M2 with other ointments or creams may lead to increased resorption of their constituent drugs.
special instructions
The interaction of the drug with other drugs has not been identified, but it should be borne in mind that the simultaneous use of the drug Komfoderm M2 with other ointments or creams may lead to increased resorption of their constituent drugs.